EUVIMEDEUVIMED entdecken
Crossref

Application of fucosylation inhibitors for production of afucosylated antibody

Ping Xu iD, Yu Chuan Ou, Michael Smith, Jim Paulson, Michael A Schmidt, Lakshmi Kandari iD, Rodney Parsons, Anurag Khetan iD

Biotechnology Progress · 2024

DOI: 10.1002/btpr.3438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Progress, 2024. Verfasst von Ping Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biologics Development, Global Product Development & Supply, Bristol Myers Squibb, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: Fucose, Cricetulus. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fucosylation is an important quality attribute for therapeutic antibodies. Afucosylated antibodies exhibit higher therapeutic efficacies than their fucosylated counterparts through antibody‐dependent cellular cytotoxicity (ADCC) mechanism. Since higher potency is beneficial in reducing dose or duration of the treatment, afucosylated antibodies have attracted a great deal of interest in biotherapeutics development. In this study, novel small molecules GDP‐D‐Rhamnose and its derivatives (Ac‐GDP‐D‐Rhamnose and rhamnose sodium phosphate) were synthesized to inhibit the enzyme in the GDP‐fucose synthesis pathway. Addition of these compounds into cell culture increased antibody afucosylation levels in a dose‐dependent manner and had no significant impact on other protein quality attributes. A novel and effective mechanism to generate afucosylated antibody is demonstrated for biologics discovery, analytical method development, process development, and other applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FucoseCricetulusAnimalsCHO CellsGlycosylationAntibodies, MonoclonalRhamnoseAntibody-Dependent Cell CytotoxicityHumansGuanosine Diphosphate Fucose

Stichwörter der Autor:innen

Chinese hamster ovaryafucosylationantibodycell culture media supplementschemicalsglycosylationinhibitorssmall molecule

Substanzen

FucoseAntibodies, MonoclonalRhamnoseGuanosine Diphosphate Fucose

Autor:innen und Institutionen

  • Biologics Development, Global Product Development & Supply, Bristol Myers Squibb, New Brunswick, New Jersey, USA.
  • Chemical Process Development, Global Product Development & Supply, Bristol Myers Squibb, New Brunswick, New Jersey, USA.

ORCID-Profile: Ping Xu, Lakshmi Kandari, Anurag Khetan

Zitieren

APA

Xu, P., Ou, Y. C., Smith, M., Paulson, J., Schmidt, M. A., Kandari, L., Parsons, R., & Khetan, A. (2024). Application of fucosylation inhibitors for production of afucosylated antibody. Biotechnology Progress. https://doi.org/10.1002/btpr.3438

Vancouver

Xu P, Ou YC, Smith M, Paulson J, Schmidt MA, Kandari L, et al. Application of fucosylation inhibitors for production of afucosylated antibody. Biotechnology Progress. 2024. doi:10.1002/btpr.3438

BibTeX
@article{Xu2024,
  author = {Xu, Ping and Ou, Yu Chuan and Smith, Michael and Paulson, Jim and Schmidt, Michael A and Kandari, Lakshmi and Parsons, Rodney and Khetan, Anurag},
  title = {Application of fucosylation inhibitors for production of afucosylated antibody},
  journal = {Biotechnology Progress},
  year = {2024},
  doi = {10.1002/btpr.3438}
}
Kostenlos starten →